![Blaise Lippa](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Blaise Lippa
Hoofd Techniek/Wetenschap/O&O bij
MORC HOLD
Profiel
Blaise Lippa is currently the Chief Scientific Officer at Morphic Therapeutic, Inc. since 2015 and at Morphic Holding, Inc. since 2022.
Previously, Blaise worked as the Senior Director-Medicinal Chemistry at Cubist Pharmaceuticals LLC.
Blaise holds a doctorate degree from Stanford University and an undergraduate degree from the University of Michigan.
Actieve functies van Blaise Lippa
| Bedrijven | Functie | Begin |
|---|---|---|
| MORC HOLD | Hoofd Techniek/Wetenschap/O&O | 12-05-2022 |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Hoofd Techniek/Wetenschap/O&O | 01-06-2015 |
Eerdere bekende functies van Blaise Lippa
| Bedrijven | Functie | Einde |
|---|---|---|
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | - |
Opleiding van Blaise Lippa
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
8
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Health Technology |
Morphic Holding, Inc.
 Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
